Akari Therapeutics, Plc

(NASDAQ) AKTX

Current Price$5.15

Market Cap$282.93M

Since IPO (2015)-100%

5 Year-100%

1 Year-88%

1 Month+61%

Akari Therapeutics, Plc Financials at a Glance

Market Cap

$282.93M

Revenue (TTM)

$0.00

Net Income (TTM)

$17.30M

EPS (TTM)

$-19.27

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$5.15

Volume

17,197.632

Open

$5.81

Price

$5.15

Volume

17,197.632

Open

$5.81

Previous Close

$5.15

Daily Range

$5.02 - $6.19

52-Week Range

$3.25 - $56.80

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$5.15

Volume

17,197.632

Open

$5.81

Previous Close

$5.15

Daily Range

$5.02 - $6.19

52-Week Range

$3.25 - $56.80

AKTX News

arrow pointing up and down with question mark

Is This Why Akari Therapetuics PLC Is Falling Today?

Brian FeroldiApr 24, 2017

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akari Therapeutics, Plc

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Abizer Gaslightwala, MBA

Website

www.akaritx.com

Headquarters

London, W1G 9RT, GB

AKTX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-68%

Return on Capital

-49%

Return on Assets

-36%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$282.93M

Shares Outstanding

45.27M

Volume

17.20K

Avg. Volume

29.80K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$17.27M

EBITDA

$17.35M

Operating Cash Flow

$10.57M

Capital Expenditure

$0.00

Free Cash Flow

$10.57M

Cash & ST Invst.

$5.20M

Total Debt

$754.00K

Akari Therapeutics, Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$282.93M

N/A

Market Cap/Employee

$35.37M

N/A

Employees

N/A

Net Income

$5.30M

-40.5%

EBITDA

$4.49M

-23.1%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$4.45M

+773.1%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$754.00K

-76.9%

Return on Assets

-36.12%

N/A

Return on Invested Capital

-48.61%

N/A

Free Cash Flow

$3.04M

-43.1%

Operating Cash Flow

$3.04M

-43.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$0.98+1.91%

DRMADermata Therapeutics, Inc.

DRMADermata Therapeutics, Inc.$1.22-3.17%

PPBTPurple Biotech Ltd.

PPBTPurple Biotech Ltd.$4.06-1.58%

XAGELongevity Health Holdings Inc.

XAGELongevity Health Holdings Inc.$0.34+6.74%

MSPRMSP Recovery, Inc.

MSPRMSP Recovery, Inc.$0.03-13.53%

CDTCDT Equity Inc.

CDTCDT Equity Inc.$1.85-7.73%

PBMPsyence Biomedical Ltd.

PBMPsyence Biomedical Ltd.$5.27-5.72%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.84+0.08%

NOKNokia

NOKNokia$13.92+0.09%

POETPoet Technologies

POETPoet Technologies$13.90+0.27%

NVTSNavitas Semiconductor

NVTSNavitas Semiconductor$22.65+0.24%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.96+0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.22-0.01%

MARAMara Holdings

MARAMara Holdings$13.39+0.03%

Questions About AKTX

What is the current price of Akari Therapeutics, Plc?

Akari Therapeutics, Plc is trading at $5.15 per share.

What is the 52-week range for Akari Therapeutics, Plc?

Over the past 52 weeks, Akari Therapeutics, Plc has traded between $3.25 and $56.80.

How much debt does Akari Therapeutics, Plc have?

As of the most recent reporting period, Akari Therapeutics, Plc reported total debt of $754,000.

How much cash does Akari Therapeutics, Plc have on hand?

Akari Therapeutics, Plc reported $5.26M in cash and cash equivalents in its most recent financial results.

What is Akari Therapeutics, Plc’s dividend yield?

Akari Therapeutics, Plc does not currently have a dividend yield.

Akari Therapeutics, Plc

Akari Therapeutics, Plc Financials at a Glance

AKTX News

Is This Why Akari Therapetuics PLC Is Falling Today?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Akari Therapeutics, Plc

AKTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Akari Therapeutics, Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AKTX

What is the current price of Akari Therapeutics, Plc?

What is the 52-week range for Akari Therapeutics, Plc?

How much debt does Akari Therapeutics, Plc have?

How much cash does Akari Therapeutics, Plc have on hand?

What is Akari Therapeutics, Plc’s dividend yield?

Premium Investing Services